학술논문
Patients’ preferences for adjuvant sorafenib after resection of renal cell carcinoma in the SORCE trial: what makes it worthwhile?
Document Type
Article
Author
Source
In Annals of Oncology February 2018 29(2):370-376
Subject
Language
ISSN
0923-7534